atenolol has been researched along with Hyperglycemia, Postprandial in 5 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okin, PM | 1 |
| Hille, DA | 1 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 1 |
| Lindholm, LH | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Gong, Y | 3 |
| McDonough, CW | 1 |
| Beitelshees, AL | 3 |
| Karnes, JH | 1 |
| O'Connell, JR | 1 |
| Turner, ST | 3 |
| Chapman, AB | 2 |
| Gums, JG | 3 |
| Bailey, KR | 1 |
| Boerwinkle, E | 3 |
| Johnson, JA | 3 |
| Cooper-DeHoff, RM | 3 |
| Moore, MJ | 1 |
| Hou, W | 1 |
| Hall, K | 2 |
| Schmidt, SO | 1 |
| Curry, RW | 1 |
| Chapman, A | 1 |
| Schwartz, GL | 1 |
| Bailey, K | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Wen, S | 1 |
| Zineh, I | 1 |
| Parekh, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
4 trials available for atenolol and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Drug Therapy, | 2014 |
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Coh | 2014 |
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
1 other study available for atenolol and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |